"No innovation is waiting for death, innovation is early death". Where is the way out for pharmaceutical enterprises to innovate?

[pharmaceutical network market analysis] recently, the 2019 (36th) national pharmaceutical industry information annual meeting was held in Lianyungang With the theme of "move with the trend and move towards the new", the conference gathered more than 2000 experts and representatives of pharmaceutical enterprises from home and abroad from the pharmaceutical industry to talk about the new future of the enterprise Under the background of the aging of our country, the number of patients with chronic diseases is increasing, and the examination and approval of innovative drugs are accelerating, "4 + 7" pilot procurement, the dynamic adjustment of medical insurance catalog, and the adoption of the new drug management law, innovative drugs have become the focus of our attention and the focus of this meeting Chen Kaixian, an academician of the Chinese Academy of Sciences, pointed out that "if we don't innovate, we will die Innovation may die early." This sentence has become a common saying in the pharmaceutical industry In fact, it also reflects the current situation faced by pharmaceutical companies On the one hand, the pharmaceutical market in China is dominated by generic drugs, about 95% of which are generic drugs With the coming of a series of heavy policies, such as the consistency evaluation of generic drugs, the pilot of the listing license system, and volume purchase, the industry said that, especially since the implementation of the 4 + 7 volume purchase and other policies, generic drugs are facing greater pressure of price reduction In addition, those pharmaceutical companies who want to survive in the generic pharmaceutical market need to be evaluated as early as possible But for some small and medium-sized enterprises, it is not easy to pass the consistency evaluation In the current context, the concentration of the generic industry is increasing, and the survival of the fittest situation is aggravating With the cost rising gradually, the generic enterprises begin to face pain relief, and need to change to the direction of innovative drugs "Innovation may die early" on the other hand, with the favorable environment for innovative drugs, the State encourages innovation and opens up a green channel for innovative drugs, innovative drugs appear in the drug market, and the market competition is very fierce Data shows that from 2007 to the first half of 2019, there were 700 domestic enterprises applying for clinical trials or production of innovative drugs and hundreds of innovative drugs At the same time, the market capacity of domestic innovative drugs will be expanded In the past six years, the compound growth rate of innovative drugs in China has reached 27% In 2018, the total sales volume of domestic innovative drugs exceeded 11 billion yuan As we all know, innovative drugs have the characteristics of high R & D risk, long cycle and high investment cost It takes 3-5 years to develop a generic drug and 10-15 years to develop a new drug It can be seen that the R & D of new drugs needs a lot of investment Without sufficient capital, it is difficult to ensure the completion of R & D projects, and the losses will be very heavy Moreover, after the success of new drug research and development, we still need to face the challenge of sales when the innovation track is crowded For example, some new drugs have a high price position, or no one pays for them, which makes it difficult for drug companies to sell them The industry believes that the pricing and internationalization of innovative drugs are a big test Where is the way out for pharmaceutical enterprises to innovate? Since we are waiting for innovation, we may die early So, where is the way out for pharmaceutical enterprises to innovate? Zhang Guimin, chairman of Lunan pharmaceutical, firmly follows the path of innovation He said, "in the next three to five years, innovation must be the king, and the remaining (winners) must be the king." Whether it's product innovation, market innovation or service innovation, as long as we realize innovation at one point and survive in the market, this "leftover" is the leftover In response to the issue of how to innovate, industry insiders have mentioned the point of "seeking differentiation" Domestic pharmaceutical enterprises can choose their targets and select their molecules according to the domestic situation It is also pointed out in the industry that the transformation of pharmaceutical enterprises is not only the way to make innovative drugs, but also the way to choose the first imitation or the innovation of dosage forms, or to acquire heavy innovative drugs by means of M & A or authorization of new drugs Du Zhenxin, chairman of Chenxin Technology Group Co., Ltd., believes that in the future, pharmaceutical enterprises will have three trends: innovation, imitation and representative factories One is from imitation to innovation, the other is to make pure generic drugs, and the third is to become a representative factory with large production capacity.